La comunità scientifica italiana (area “life sciences”) e la sfida dei progetti comunitari

1. La comunità scientifica italiana (area “life sciences”) e • la sfida dei progetti comunitari

2. applications 1.600 1.400 1.200 1.000 800 600 400 200 0 DE UK IT FR NL ES SE BE DK PL Fi AT GR HU CZ PT IE EE SI SK LT CY LV Lu MT

3. percentuale di successo 40,00% 35,00% 30,00% 25,00% 20,00% 15,00% 10,00% 5,00% 0,00% EU BE FR UK IE NL DE AT DK IT SE ES Fi PT HU EE GR CZ LT CY SI PL Lu SK LV MT

4. percentuale di partecipazione di ricercatori italiani 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% UNI REC SME IND OTHER

5. percentuale di successo 40,00% 35,00% 30,00% 25,00% 20,00% 15,00% 10,00% 5,00% 0,00% Other All UNI REC SMEs IND percentuale di partecipazione 70% 60% 50% IT 40% 30% 20% FR 10% 0% UNI REC SME IND OTHER

6. Specializzazione scientifica Italiana - Pubblicazioni 0,200 0,000 -0,200 Symmetric Relative Specialization Index (RSI) -0,400 Gastroenterology and Hepatology Hematology Oncogenesis & Cancer Research Oncology Pharmacology/Toxicology Space Science Instrumentation/Measurement Physics Inorganic&Nuclear Chemistry 1992-1994 1998-2000 -0,600 -0,800 -1,000 01 02 03 04 05 06 07 08 09 10 11 12 13 14 Aree disciplinari

7. La comunità scientifica italiana (area “life sciences”) e • la sfida dei progetti comunitari • I temi su cui abbiamo più probabilità di ottenere finanziamenti

8. La comunità scientifica italiana (area “life sciences”) e • la sfida dei progetti comunitari • I temi su cui abbiamo più probabilità di ottenere finanziamenti • Cosa chiede la comunità scientifica

9. a) incrementare i finanziamenti; • b) eliminare l’obbligo di creare networks di ricerca per accedere ai finanziamenti a meno che non esistano delle reali esigenze di collaborazione; • c) offrire spazi significativi al finanziamento di nuovi gruppi di ricerca; • d) riservare una quota significativa delle risorse al finanziamento di progetti di ricerca liberi, cioè non finalizzati al raggiungimento di obiettivi preordinati; • e) dare spazio alla mobilità dei ricercatori, non limitandola alle attività di formazione. • i) uniformità delle politiche di finanziamento pubblico; • ii) coordinamento delle politiche di finanziamento nazionali e europee; • iii) incentivi alla mobilità transnazionale dei group leaders; • iv) accesso a tutti i ricercatori europei alle fonti di finanziamento delle singole nazioni.

11. Collaborative research will constitute the bulk and the core of EU research funding Joint Technology Initiatives will mainly be created on the basis of the work undertaken by the European Technology Platforms - Emphasis on research themes rather than on “instruments” - Significant simplification of its operation - Focus on developing research that meets the needs of European industry, through the work of Technology Platforms and the new Joint Technology Initiatives - Establishment of a European Research Council, funding the best of European science - Integration of International cooperation in all four programmes - Development of Regions of Knowledge - A Risk-Sharing Finance Facility aimed at fostering private investment in research Lower number of partners in consortia and a greater focus on smaller projects

12. Proposal for a COUNCIL DECISION concerning the Specific Programme “Cooperation” implementing the Seventh Framework Programme (2007-2013) of the European Community for research, technological development and demonstration activities • Biotechnology, generic tools and technologies for human health • This activity aims at developing and validating the necessary tools and technologies that will make possible the production of new knowledge and its translation into practical applications in the area of health and medicine. • – High-throughput research • The focus will be on new technologies for: sequencing; gene expression, genotyping and phenotyping; structural genomics; bioinformatics and systems biology; other “omics”. • – Detection, diagnosis and monitoring: • The focus will be on a multidisciplinary approach integrating areas such as: molecular and cellular biology, physiology, genetics, physics, chemistry, nanotechnologies, microsystems, devices and information technologies. Non- or minimally- invasive and quantitative methods and quality assurance aspects will be emphasised. • – Innovative therapeutic approaches and interventions: • The focus will be on gene and cell therapy, regenerative medicine, transplantation, immunotherapy and vaccines, and other medicines. Related technologies, such as advanced targeted delivery systems, advanced implants and prosthetics, and non- or minimally-invasive technology-assisted interventions will also be addressed. • – Predicting suitability, safety and efficacy of therapies • The focus will be on approaches such as pharmacogenomics, in silico, in vitro (including alternatives to animal testing) and in vivo methods and models.

13. Translating research for human health This activity aims at increasing knowledge of biological processes and mechanisms involved in normal health and in specific disease situations, to transpose this knowledge into clinical applications, and to ensure that clinical data guide further research. – Integrating biological data and processes: large-scale data gathering, systems biology. Large scale data gathering: The focus will be on: genomics; proteomics; population genetics; comparative and functional genomics. - Systems biology: the focus will be on multidisciplinary research that will integrate a wide variety of biological data and will develop and apply system approaches to understand and model biological processes. – Research on the brain and related diseases, human development and ageing. Brain and brain-related diseases The focus will be to explore brain functions, from molecules to cognition, and to address neurological and psychiatric diseases and disorders, including regenerative and restorative therapeutic approaches. Human development and ageing: The focus will be on the study of human and model systems, including interactions with factors such as environment, behaviour and gender. – Translational research in major infectious diseases: to confront major threats to public health. Anti-microbial drug resistance: the focus will be on combining basic research on molecular mechanisms of resistance, microbial ecology and host-pathogen interactions with clinical research towards new interventions to reduce the emergence and spread of multi-drug resistant infections. HIV/AIDS, malaria and tuberculosis: the focus will be on developing new therapies, diagnostic tools, preventive vaccines and chemical transmission barriers such as HIV microbicides Emerging epidemics: the focus will be on confronting emerging pathogens with pandemic potential including zoonoses (e.g. SARS and highly pathogenic influenza). – Translational research in other major diseases. Cancer Cardiovascular disease Diabetes and obesity Rare diseases Other chronic diseases

14. Optimising the delivery of health care to European citizens • This activity aims at providing the necessary basis both for informed policy decisions on health systems and for more effective strategies of health promotion, disease prevention, diagnosis and therapy. • – Enhanced health promotion and disease prevention: • – Translating clinical research into clinical practice • – Quality, solidarity and sustainability of health systems